| NCT ID | NCT02900521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Cerebral (CVAs) |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2008-01 |
| Primary Completion | 2016-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2008-01 with a primary completion date of 2016-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.
Eligibility Criteria
Inclusion Criteria: * Diagnostic validated for one of the following pathologies: * Ischemic stroke, * Non-traumatic intracranial hematoma * Cerebral venous thrombosis Diagnostic after December 31, 2007 Age \> 15 years on the date of the diagnostic Patient domiciled at the time of the diagnostic in one of the 79 communes defined beforehand Exclusion Criteria: * Age ≤ 15 years * Validated diagnosis (see below, § 4.2.2) of aneurysmal subarachnoid hemorrhage cerebrovascular * Diagnosis made before 1 January 2008 * Unconfirmed diagnosis * Patient domiciled outside the previously defined area of residence
Contact & Investigator
Serge TIMSIT
PRINCIPAL INVESTIGATOR
CHRU La Cavale Blanche - BREST - FRANCE
Frequently Asked Questions
Who can join the NCT02900521 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Cerebral (CVAs). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02900521 currently recruiting?
Yes, NCT02900521 is actively recruiting participants. Contact the research team at serge.timsit@chu-brest.fr for enrollment information.
Where is the NCT02900521 trial being conducted?
This trial is being conducted at Brest, France.
Who is sponsoring the NCT02900521 clinical trial?
NCT02900521 is sponsored by University Hospital, Brest. The principal investigator is Serge TIMSIT at CHRU La Cavale Blanche - BREST - FRANCE. The trial plans to enroll 15,000 participants.